Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study's analysis of heavily pretreated patients.
Sebastiano ButiAlessandro OlivariCristina MasiniDavide BimbattiDonata SartoriPaola ErmacoraCarlo CattriniMaria Giuseppa VitaleErnesto RossiClaudia MucciariniMimma RizzoMichele SisaniMatteo SantoniGiandomenico RovielloVeronica MollicaVincenza ConteducaFrancesco GrilloneMarika CinauseroGiuseppe PratiFrancesco AtzoriMarco StellatoFrancesco MassariMelissa BersanelliPublished in: Therapeutic advances in urology (2024)
Our findings suggest a clinically relevant effectiveness of lenvatinib plus everolimus combination with an acceptable toxicity profile for heavily pretreated patients with mRCC.